SBE-313

N/A

Report date: 2026/04/29 20:02:18

Base Information

Drug NameSBE-313
Drug Alias NameSBE313SBE-313
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-Epidermal growth factor receptor erbB1Anti-Receptor tyrosine-protein kinase erbB-3
TargetsEpidermal growth factor receptor erbB1Receptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSamsung Bioepis Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPhrontline Biopharma Co LtdSamsung Bioepis Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A